Drawing for REVAPP

USPTO serial 87232950

REVAPP

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
KHAN, AHSEN M
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with REVAPP?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Camille M. Miller

CAMILLE M. MILLER COZEN O'CONNOR1650 Market Street, Suite 2800One Liberty PlacePHILADELPHIA, PA 19103

Goods and services

ClassDescriptionStatusFirst use
009Computer application software for mobile phones, portable media players, handheld computers, namely, software for use in database management, for use in electronic storage of data, for use as a spreadsheet, and for word processing, all for use by patients and health care professionals in connection with providing medical counseling and medical information in the field of lenalidomide and safety issues pertaining to lenalidomide; downloadable software in the nature of a mobile application for use in database management, for use as a spreadsheet, for word processing, for electronic storage of data, in connection with providing medical counseling and medical information in the field of lenalidomide and safety issues pertaining to lenalidomide; computer software for use on mobile and cellular phones in the field of health care and dosing of pharmaceuticals for use in accessing databases and websites in order to provide drug dosage and administration information in the field of lenalidomide; downloadable electronic software for use on mobile and cellular phones, handheld computers in the field of health care and dosing of pharmaceuticals for use in accessing databases and websites in order to provide drug dosage and administration information in the field of lenalidomide; computer application software for mobile phones, portable media players, handheld computers, namely, software for use in database management, for use in electronic storage of data, for use as a spreadsheet, and for word processing, all for use by patients and health care professionals in connection with providing medical counseling and medical information in the field of lenalidomide and safety issues pertaining to lenalidomideACTIVE—
042Software as a service (SAAS) featuring software for tracking and monitoring medication intake and safety issues pertaining to lenalidomide, all for use by patients and health care professionals in connection with providing medical counseling and medical information in the field of lenalidomide and safety issues pertaining to lenalidomide; providing information about the results of clinical trials for pharmaceutical products; providing temporary use of non downloable online software applications containing information on the use of pharmaceutical products and for calculating use of medicine in the field of lenalidomide and safety issues pertaining to lenalidomide; providing temporary use of non-downloadable electronic software for use on mobile and cellular phones, handheld computers in the field of health care and dosing of pharmaceuticals for use in accessing databases and websites in order to provide drug dosage and administration information in the field of lenalidomide and safety issues pertaining to lenalidomide; providing online, non-downloadable computer application software for mobile phones, portable media players, handheld computers, namely, software for use in database management, for use in electronic storage of data, for use as a spreadsheet, and for word processing, all for use by patients and health care professionals in connection with providing medical counseling and medical information in the field of lenalidomide and safety issues pertaining to lenalidomideACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Sep 21, 2020MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Sep 21, 2020ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Dec 27, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Dec 26, 2019EX5GSOU EXTENSION 5 GRANTED—
Dec 26, 2019AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Dec 16, 2019EXT5SOU EXTENSION 5 FILED—
Dec 16, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 8, 2019DOCKASSIGNED TO EXAMINER—
Jun 11, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jun 7, 2019EX4GSOU EXTENSION 4 GRANTED—
Jun 7, 2019EXT4SOU EXTENSION 4 FILED—
Jun 7, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Dec 8, 2018EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Dec 6, 2018EX3GSOU EXTENSION 3 GRANTED—
Dec 6, 2018EXT3SOU EXTENSION 3 FILED—
Dec 6, 2018EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 18, 2018EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 16, 2018EX2GSOU EXTENSION 2 GRANTED—
Jul 16, 2018EXT2SOU EXTENSION 2 FILED—
Jul 16, 2018EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 18, 2018EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 16, 2018EX1GSOU EXTENSION 1 GRANTED—
Jan 16, 2018EXT1SOU EXTENSION 1 FILED—
Jan 16, 2018EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Aug 15, 2017NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jun 20, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jun 20, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 31, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
May 10, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 19, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 18, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 18, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 13, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 13, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 13, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 6, 2017DOCKASSIGNED TO EXAMINER—
Nov 17, 2016TAEATEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED—
Nov 17, 2016PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Nov 17, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Nov 14, 2016NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance